PTTG Binding Factor (PBF) - a Novel Transforming Gene in Thyroid Tumorigenesis

Research output: Contribution to journalArticle

Standard

Harvard

APA

Vancouver

Author

Bibtex

@article{9c76d74ba55e449cb9f2921f453a34a9,
title = "PTTG Binding Factor (PBF) - a Novel Transforming Gene in Thyroid Tumorigenesis",
abstract = "Context: There are currently no clear markers for the detection of differentiated thyroid cancer and its recurrence. Pituitary tumor transforming gene (PTTG) is a protooncogene implicated in the pathogenesis of multiple tumor types, which stimulates fibroblast growth factor-2 secretion via PTTG binding factor (PBF). Objective: The aim of this study was to ascertain whether PBF expression is associated with thyroid cancer outcome. Design: PBF expression was measured at the mRNA and protein level. Tissue was collected during surgery, with normal samples being taken from the contralateral lobe. In vitro studies ascertained the ability of PBF to transform cells and form tumors in nude mice and its subcellular localization. Setting: The study was conducted at a primary care/referral center. Patients: Thyroid tumors were collected from a series of 27 patients undergoing surgical excision of papillary and follicular thyroid tumors. Intervention: No intervention was conducted. Main Outcome Measure: The expression of PBF in thyroid cancers compared with normal thyroid, hypothesized before the investigation to be raised in tumors, was the main outcome measure. Results: PBF mRNA expression was higher in differentiated thyroid carcinomas than in normal thyroid (P <0.001; n = 27) and was independently associated with tumor recurrence (P = 0.002; R-2 = 0.49). PTTG was able to up-regulate PBF mRNA expression in vitro (P <0.001; n = 12), and stable overexpression of PBF in NIH3T3 cells resulted in significant colony formation (P <0.001; n = 12). In vivo, stable sc overexpression of PBF induced tumor formation in athymic nude mice. Conclusions: PBF is an additional prognostic indicator in differentiated thyroid cancer that is transforming in vitro and tumorigenic in vivo.",
author = "Anna Stratford and Kristien Boelaert and Lesley Tannahill and Dae Kim and Adrian Warfield and Margaret Eggo and Neil Gittoes and Lawrence Young and Jayne Franklyn and Christopher McCabe",
year = "2005",
month = apr,
day = "5",
doi = "10.1210/jc.2005-0523",
language = "English",
volume = "90",
pages = "4341--4349",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Endocrine Society",
number = "7",

}

RIS

TY - JOUR

T1 - PTTG Binding Factor (PBF) - a Novel Transforming Gene in Thyroid Tumorigenesis

AU - Stratford, Anna

AU - Boelaert, Kristien

AU - Tannahill, Lesley

AU - Kim, Dae

AU - Warfield, Adrian

AU - Eggo, Margaret

AU - Gittoes, Neil

AU - Young, Lawrence

AU - Franklyn, Jayne

AU - McCabe, Christopher

PY - 2005/4/5

Y1 - 2005/4/5

N2 - Context: There are currently no clear markers for the detection of differentiated thyroid cancer and its recurrence. Pituitary tumor transforming gene (PTTG) is a protooncogene implicated in the pathogenesis of multiple tumor types, which stimulates fibroblast growth factor-2 secretion via PTTG binding factor (PBF). Objective: The aim of this study was to ascertain whether PBF expression is associated with thyroid cancer outcome. Design: PBF expression was measured at the mRNA and protein level. Tissue was collected during surgery, with normal samples being taken from the contralateral lobe. In vitro studies ascertained the ability of PBF to transform cells and form tumors in nude mice and its subcellular localization. Setting: The study was conducted at a primary care/referral center. Patients: Thyroid tumors were collected from a series of 27 patients undergoing surgical excision of papillary and follicular thyroid tumors. Intervention: No intervention was conducted. Main Outcome Measure: The expression of PBF in thyroid cancers compared with normal thyroid, hypothesized before the investigation to be raised in tumors, was the main outcome measure. Results: PBF mRNA expression was higher in differentiated thyroid carcinomas than in normal thyroid (P <0.001; n = 27) and was independently associated with tumor recurrence (P = 0.002; R-2 = 0.49). PTTG was able to up-regulate PBF mRNA expression in vitro (P <0.001; n = 12), and stable overexpression of PBF in NIH3T3 cells resulted in significant colony formation (P <0.001; n = 12). In vivo, stable sc overexpression of PBF induced tumor formation in athymic nude mice. Conclusions: PBF is an additional prognostic indicator in differentiated thyroid cancer that is transforming in vitro and tumorigenic in vivo.

AB - Context: There are currently no clear markers for the detection of differentiated thyroid cancer and its recurrence. Pituitary tumor transforming gene (PTTG) is a protooncogene implicated in the pathogenesis of multiple tumor types, which stimulates fibroblast growth factor-2 secretion via PTTG binding factor (PBF). Objective: The aim of this study was to ascertain whether PBF expression is associated with thyroid cancer outcome. Design: PBF expression was measured at the mRNA and protein level. Tissue was collected during surgery, with normal samples being taken from the contralateral lobe. In vitro studies ascertained the ability of PBF to transform cells and form tumors in nude mice and its subcellular localization. Setting: The study was conducted at a primary care/referral center. Patients: Thyroid tumors were collected from a series of 27 patients undergoing surgical excision of papillary and follicular thyroid tumors. Intervention: No intervention was conducted. Main Outcome Measure: The expression of PBF in thyroid cancers compared with normal thyroid, hypothesized before the investigation to be raised in tumors, was the main outcome measure. Results: PBF mRNA expression was higher in differentiated thyroid carcinomas than in normal thyroid (P <0.001; n = 27) and was independently associated with tumor recurrence (P = 0.002; R-2 = 0.49). PTTG was able to up-regulate PBF mRNA expression in vitro (P <0.001; n = 12), and stable overexpression of PBF in NIH3T3 cells resulted in significant colony formation (P <0.001; n = 12). In vivo, stable sc overexpression of PBF induced tumor formation in athymic nude mice. Conclusions: PBF is an additional prognostic indicator in differentiated thyroid cancer that is transforming in vitro and tumorigenic in vivo.

UR - http://www.scopus.com/inward/record.url?scp=23044451130&partnerID=8YFLogxK

U2 - 10.1210/jc.2005-0523

DO - 10.1210/jc.2005-0523

M3 - Article

VL - 90

SP - 4341

EP - 4349

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

ER -